Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
AI tools like those from GE and AWS aim to revolutionize healthcare by unlocking vast amounts of underutilized medical data.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Southern Miss advances biomaterials research for immune disease treatment with a $2.5M collaboration, boosting Mississippi's biotech.
Cathie Wood's ARK shifts focus, selling Ginkgo and Coinbase, while investing in 10X Genomics and Roku in a biotech-centered portfolio ...
Researchers have successfully developed a single-dose vaccine that prompts the production of T-cells and "memory" B cells to fight against ...
Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
Clinical-stage biotech company Coya Therapeutics expands its IP portfolio with a license for a novel combination therapy using low dose ...
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.